How Will the Market React to Amgen, Inc. (AMGN) Stock Getting a Bearish Rating

Amgen, Inc. (AMGN) stock is lower by 1.10% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Amgen, Inc. has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on AMGN!

See Full AMGN Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With AMGN Stock Today?

Amgen, Inc. (AMGN) stock is trading at $206.81 as of 1:11 PM on Thursday, Oct 14, a rise of $3.19, or 1.57% from the previous closing price of $203.61. The stock has traded between $204.49 and $207.50 so far today. Volume today is low. So far 1,327,572 shares have traded compared to average volume of 2,642,031 shares. To see InvestorsObserver's Sentiment Score for Amgen, Inc. click here.

More About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), and Lumakras (lung cancer). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira). Click Here to get the full Stock Report for Amgen, Inc. stock.